Targeted protein degradation, oncology research, and biotech innovation by C4 Therapeutics
C4 Therapeutics presents data on cemsidomide plus dexamethasone trial at EHA2026
C4 Therapeutics revealed new analysis from its fully enrolled Phase 1 trial studying cemsidomide in combination with dexamethasone for patients with relapsed or refractory multiple myeloma at ...
Executive team at C4 Therapeutics, Inc. set for Jefferies conference fireside chat
C4 Therapeutics, Inc. announced its management team will participate in a fireside chat at the Jefferies Global Healthcare Conference. The session is scheduled for June 4 at 9:20 am ET. The ...
C4 Therapeutics, Inc. unveils Phase 2 trial progress for cemsidomide at ASCO26
C4 Therapeutics, Inc. announced plans to present a Trial in Progress poster at ASCO26, focusing on its Phase 2 MOMENTUM clinical trial of cemsidomide. The therapy is a potential best-in-class ...
Clinical trial participation drives development of innovative treatments, C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is emphasizing the essential role of clinical research and patient participation in the development of new medicines. The company reaffirmed its commitment to innovative ...
C4 Therapeutics, Inc. to present new cemsidomide Phase 1 data at EHA Hematology 2026 Congress
C4 Therapeutics, Inc. announced it will present a poster with further analysis from its Phase 1 study of cemsidomide, a potential best-in-class IKZF1/3 degrader, in combination with dexamethasone ...
Roche and C4 Therapeutics deepen collaboration to pursue novel cancer-targeting platforms
C4 Therapeutics, Inc. has announced an expansion of its long-term partnership with Roche to further research and develop next-generation degrader-antibody conjugates (DACs) targeting ...
C4 Therapeutics, Inc. advances pipeline as SVP Shagha Russell drives cemsidomide toward regulatory studies
C4 Therapeutics, Inc. announced that Shagha Russell, senior vice president and general counsel, has played a pivotal role in steering cemsidomide toward regulatory studies. Russell, who joined ...
Cemsidomide design includes extended treatment holiday for safer dosing, C4 Therapeutics asserts
C4 Therapeutics, Inc. presented new details on cemsidomide, an experimental IKZF1/3 degrader that could set a new standard in its class. The innovative regimen incorporates a 14 day treatment ...
C4 Therapeutics, Inc. to join Barclays global healthcare conference fireside chat
C4 Therapeutics, Inc. will participate in a fireside chat at the Barclays 28th Annual Global Healthcare Conference on March 10. The event, hosted by Barclays, brings together leading healthcare ...
C4 Therapeutics to present at TD Cowen 46th Annual Healthcare Conference March 3
C4 Therapeutics, Inc. will present and participate in a fireside chat at the TD Cowen 46th Annual Healthcare Conference on March 3. The event serves as a key gathering for healthcare leaders and ...
C4 Therapeutics, Inc. posts fourth quarter and full year 2025 financial results
C4 Therapeutics, Inc. has released its financial results for the fourth quarter and full year 2025, along with a summary of recent business developments. The company detailed its latest ...
